Trending...
- Governor Gavin Newsom signs SB 27, strengthening California's CARE Act and expanding access to behavioral health services
- Cent Capital Launches FinPedia, a Free Financial Literacy Resource for Personal Finance and Investing
- RNHA FL Unveils Bold New Leadership Ahead of 2026 Elections
HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to be Owned by NRXP Shareholders, and New Investors. Effort to be Funded Apart from NRXP.
WILMINGTON, Del. - Californer -- For more information on $NRXP visit: https://www.nrxpharma.com/ OR https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on The Californer
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on The Californer
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on The Californer
- Industrial CNC Machinery automates machining processes with high accuracy and reduced labor costs
- For Nat'l. Novel Writing Month: Check out The Next Big Thing in Entertainment for Books, Movies & TV
- MetroWest wellness: Holliston farmhouse spa unveils Centerpoint Studio
- California: Governor Newsom proclaims Indigenous Peoples' Day
- Nomadness Offices Now available in Mammoth Lakes and Steamboat Springs
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on The Californer
- Super ChatGPT Hack - No Coding Required! 10X Your Income (Learning) with this Amazing ChatGPT Sec
- Cancer Survivor Roslyn Franken Marks 30-Year Milestone with Empowering Gift for Women
- ICYMI: Governor Newsom congratulates California Nobel laureates, underscoring the state's global dominance in science and innovation
- Hard Hitting Political Issues Column in Noted African American Newspaper Now Facebook Livestreamed
- Record-breaking quarter: California reaches historic high in ZEV sales
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on The Californer
- Why Jobseekers Should Invest in a Professional Resume Writer
- Voices for Humanity Leads Resurgence of Moral Values in Hungary with Antónia and Ferenc Novák
- Richline Transportation Elevates San Diego Airport Transfers with Luxury Black Car Service
- RJ Grimshaw Launches "The AI EDGE" A Practical Guide Where Leadership Meets Innovation
- WECS TV Show San Francisco ~ Dallas Spotlights Sherri Young, AASC Executive Director
- California: Governor Newsom statement on the passing of Diane Keaton
- California: Governor Newsom issues legislative update 10.11.25
- Probate Shepherd® Announces a New Member Probate Attorney in Sugar Land, TX
- California: Governor Newsom signs SB 41 to lower the cost of prescription drugs
- New Song "Soccer Will Soar" Celebrates Upcoming 2026 World Cup and Welcomes Fans to the USA
- New Sports Card Addition to The Shoppes at Carlsbad
- Governor Newsom signs legislative package to expand services and resources for Californian women
- Live Good Leads with Love: Creating Opportunity, Protecting the Vulnerable and Inspiring Hope
- California to provide critical support for workers hurt by Trump's failure, federal shutdown
- California: Governor Newsom signs bill to prosecute threats against schools, workplaces, places of worship, and hospitals
- Probate Shepherd® Announces a New Member Probate Attorney in The Woodlands, TX
- Probate Shepherd® Announces a New Member Probate Attorney in Conroe, TX
- LoveSetMatch Receives LA County Commendation for Service and Community Impact
- Taraji P. Henson's Boris Lawrence Henson Foundation (BLHF) Announce 5th Annual Can We Talk? Arts & Wellness Summit and "i AM The Table Benefit Brunch
- Aligned Healthy Wealth Retreat Empowers Entrepreneurs & Supports Child-Safety Education in San Diego